Tafolecimab Injection. 通用名：托莱西单抗注射液.

Similac® (tolerizumab injection, an anti-PCSK9 monoclonal antibody [10]). In August 2023, it was approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. [1] Similac® is China’s first domestically developed PCSK9 inhibitor approved, and is also Innovent’s first product in the field of cardiovascular disease. [4] It is the tenth product launched in Innovent’s 12th anniversary. [5] Similac® (tolerizumab injection, an anti-PCSK9 monoclonal antibody [10]). In August 2023, it was approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. [1] Similac® is China’s first domestically developed PCSK9 inhibitor approved, and is also Innovent’s first product in the field of cardiovascular disease. [4] It is the tenth product launched in the 12th anniversary of Innovent Biologics. [5]

Simbrel® (Tolerizumab Injection) is an innovative biological drug independently developed by Innovent Biologics. It is an IgG2 fully human monoclonal antibody that can specifically bind to the PCSK9 (proprotein convertase subtilisin/kexin type 9) molecule and increase the level of low-density lipoprotein receptor (LDLR) by reducing PCSK9-mediated endocytosis of low-density lipoprotein receptor (LDLR), thereby increasing LDL-C clearance and lowering LDL-C levels [14].
Indications
Report
Editor
Simbrel® (Tolerizumab Injection) is approved in China for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia who are unable to achieve low-density lipoprotein cholesterol (LDL-C) targets despite moderate or higher doses of statins. [1]